Geistlich - Indication sheets X3 - Failure Management

Indication Sheet X3 31430.1/1008/e Failure Management Literature references  Schwarz et al. Journal of Clinical Periodontology. 2006;33:491-499. H  ealing of intrabony peri-implantitis defects following application of a nanocrystalline hydroxyapatite (Ostim) or a bovine-derived xenograft (Bio-Oss) in combination with a collagen membrane (Bio-Gide). A case series. 1  Schwarz et al. Journal of Clinical Periodontology. 2006;33:584-595. Influence of different treatment approaches on non-submerged and submerged healing of ligature induced peri-implantitis lesions: an experimental study in dogs. 2  Schwarz et al. Clinical Oral Implants Research. 2007;18:161-170. Comparison of naturally occurring and ligature-induced peri-implantitis bone defects in humans and dogs. 3  Schwarz et al. Journal of Clinical Periodontology. 2008;35:80-87. T  wo-year clinical results following treatment of peri-implantitis lesions using a nanocrystalline hydroxyapatite or a natural bone mineral in combination with a collagen membrane. 4  Schwarz et al. Journal of Clinical Periodontology. 2009;36:807-814. S  urgical regenerative treatment of peri-implantitis lesions using a nanocrystalline hydroxyapatite or a natural bone mineral in combination with a collagen membrane: a four-year clinical follow-up report. 5  Schwarz et al. Journal of Clinical Periodontology. 2010;37:449-455. Impact of defect configuration on the clinical outcome following surgical regenerative therapy of periimplantitis. 6  Schwarz & Becker. Quintessence Publishing Co. Ltd. London, 2010. Peri-implant Infection. Etiology, Diagnosis and Treatment. 7 Treatment concepts for Peri-Implantitis by PD Dr. Frank Schwarz, Dr. Narja Sahm and Prof. Dr. Juergen Becker, Duesseldorf, Germany Contact > PD Dr. Frank Schwarz, Heinrich Heine University, Westdeutsche Kieferklinik, Moorenstrasse 5, 40225 Duesseldorf, Germany telephone: +49 211 811 81 49, fax: +49 211 171 35 42, e-mail: Frank.Schwarz@med.uni-duesseldorf.de >  herapeutic strategies for intraosseous and supracrestal defect components. T >  he treatment steps: decontamination, implantoplasty, and augmentation / guided bone regeneration T (GBR) can deliver good results. >  eistlich Bio-Oss®, Geistlich Bio-Gide® and Geistlich Mucograft® are important components of G treatment concepts for tissue regeneration. Further Indication Sheets >  free delivery please contact: www.geistlich.com/indicationsheets For >  you no longer wish to collect Indication Sheets, please unsubscribe with your local distribution partner If 1. Synopsis: Regenerative Therapy Criteria Regenerative Measure Intrabony Component Geistlich Bio-Oss® (0.25–1 mm) Gesitlich Bio-Gide® Double Layer Technique Supracrestal Component (< 1 mm) Geistlich Bio-Oss® (1–2 mm) Contour Augmentation Supracrestal Component (> 1 mm) Dehisced Areas Implantoplasty Thin Mucosa Geistlich Mucograft® Visualisation Geistlich Pharma AG Business Unit Biomaterials CH-6110 Wolhusen phone +41 41 492 56 30 fax +41 41 492 56 39 www.geistlich-pharma.com © 5 1 6